Use of basiliximab with mycophenolate mofetil in kidney transplantation

Transplantation Proceedings

Volumn 35, Issue 8, 2003, Pages 2881-2884

  Baron, P W ^a   Weissman, J ^a   Ojogho, O N ^a   Sahney, S ^a   Cutler, D ^a   James, S ^a   Oculam, C ^a   Abdelhalim, F ^a   Nehlsen Cannarella, S L ^a   Teichman, S ^a   Concepcion, W ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RACE; RISK FACTOR; STEROID THERAPY; SURVIVAL RATE;

EID: 9144256668     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.10.080     Document Type: Article

References (6)

1. Kahan B.D., Rajagopalan P.R., Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 67:1999;276.
2. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 350:1997;1193.
3. Ponticelli C., Yussim A., Cambi V., et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation. 72:2001;1261.
4. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 75:2003;37.
5. Boggi U., Vistoli F., Del Chiaro M., et al. CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab in cadaveric kidney transplantation. Transplant Proc. 33:2001;3199.
6. Gonwa T.A., Mai M.L., Smith L.B., et al. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation:use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody. Clin Transplant. 16:2002;144.